Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial With Stent Evaluation in All-comers IV

Trial Profile

Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial With Stent Evaluation in All-comers IV

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms BIONYX; TWENTE IV

Most Recent Events

  • 13 Jul 2021 Status changed from active, no longer recruiting to completed, according to Results published in the Circulation Journal.
  • 13 Jul 2021 Results published in the Circulation Journal
  • 17 May 2021 Results (N=2488) of an analysis assessing the 3-year outcome after percutaneous coronary intervention presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top